论文部分内容阅读
目的：探讨孟鲁司特钠联合布地奈德与异丙托溴铵治疗儿童哮喘的临床疗效。方法75例支气管哮喘患儿随机分为治疗组（n=40）和对照组（n=35）。对照组给予雾化吸入布地奈德和异丙托溴胺治疗。治疗组在对照组常规治疗的基础上加用孟鲁司特钠口服（3～5岁服用4 mg，6～14岁服用5 mg，QN），两组总疗程均为3个月。对两组的临床疗效及肺功能进行比较分析。结果治疗组患儿总有效率（87.5%）明显高于对照组（65.7%），差异有统计学意义（P﹤0.05）；治疗组患儿经过治疗后肺功能第一秒用力呼气容积（FEV1）及最大呼气流量（PEF）明显改善，分别与对照组比较，差异均有统计学意义（P﹤0.05）。结论孟鲁司特钠联合布地奈德和异丙托溴铵雾化吸入治疗儿童哮喘临床疗效显著，值得临床推广应用。“,”Objective To investigate the clinical efficacy of montelukast combined with budesonide and ipratropium bromide inhalation therapy on children with bronchial asthma.Methods 75 cases of children with bronchial asthma were randomly divided into two groups: the treatment group (n=40) and the control group (n=35). The cases in control group were treated by aerosol inhalation of budesonide and ipratropium bromide, the cases in treatment group were treated with montelukast (3~5 years old, 4 mg; 6~14 years old, 5 mg, po. once per night, for three months) combined with budesonide and ipratropium bromide. The clinical curative effect and pulmonary function in two groups were analyzed before and after treatment.Results The total effective rate in the treatment group (87.5%) was higher than that in the control group (65.7%), the difference was statistically signiifcant (P﹤0.05). Compared with the control group, FEV1 and PEF in the treatment group after treatment were markedly improved, the difference was statistically signiifcant (P﹤0.05).Conclusion The curative effect of montelukast combined with budesonide and ipratropium bromide inhalation therapy on children with bronchial asthma is signiifcant, worthy of clinical popularization and application.